The Global Pathogen Analysis Service Limited (GPAS Ltd) is transforming global health by providing equitable access to rapid genomic sequencing analysis, to help better manage the spread of infectious diseases worldwide.
By using GPAS, decision makers, such as public health leaders, can access accurate and comparable information about the spread and evolution of infectious diseases, and enable data driven policy decisions.
Starting with SARS-CoV-2, GPAS aims to be the world’s leading technology platform to perform genomic sequencing analysis for pathogens.
A not-for-profit based in Oxford, UK, GPAS Ltd’s SARS-CoV-2 technology is free at the point of service for academic and research laboratories and public health bodies, in low and middle income countries (LMICs).
How it works
We’re creating a global community of users who are collaborating via rapid and effective data sharing, helping to respond to the challenges of endemic and epidemic infectious diseases.
Built by a long-established world-leading pathogen genomics team from the University of Oxford, and supported by the cloud computing scale and security provided by Oracle, GPAS offers a transformative global solution that automates and vastly accelerates the processing, analysing and comparing of genomic sequencing data.
We’re already delivering a significant impact to global health as we evolve from start-up to scale-up.